Havana, Cuba: The phase three clinical trial carried out by the Pasteur Institute, of Iran, with the anti-Covid-19 Soberana 02 and Soberana Plus vaccines, from Cuba, showed excellent results in that country, the Finlay Institute of Vaccines reported on Monday (IFV).
The Cuban entity, in charge of these immunogens, detailed that the double-blind, randomized and placebo-controlled study included 24 thousand subjects, to whom Sovereign-02 was applied in a two-dose regimen, in eight cities, and a booster dose with the Sovereign-Plus vaccine, in two other cities, Radio Habana Cuba publishes.
During the analysis, the Delta variant of the SARS-CoV-2 virus, which causes Covid-19, had 71.9 percent prevalence in July and was already 95.4 percent in August, making it widely predominant.
According to the IFV “The intermediate analysis showed in the regimen of two doses 76.8 percent and in the regimen of three 91.7 percent of efficacy of the vaccine to prevent hospitalization by Covid-19”.
Likewise, 87.9 percent of the participants in the two-dose regimen group and 98.8 percent of the three-dose group showed a four-fold increase in antibodies.
An independent committee developed the phase three clinical trial on the Sovereign series in the Iranian population aged 18 to 80 years in order to arrive at these results, as part of the collaboration between the Pasteur Institute of Iran and the Finlay Vaccine Institute.
“The trial in the Persian country confirmed the results obtained in Cuba, even against the Delta variant,” the IFV Research Director, Dagmar García, pointed out in her Twitter account.
Last July, both institutions announced the start of joint manufacture of the Sovereign 02 vaccine in Iran, and it will be known there as PastuCovac.
After the announcement of the results of this trial, they designed and produced a vaccine with unique characteristics, which has a booster dose and is also useful for ages three to 18 years and older, said the director of the Pasteur Institute, Alireza Biglari.